Loading...
Pharmacokinetics of Cabotegravir in Subjects with Severe Renal Impairment
BACKGROUND: Cabotegravir (CAB) is an integrase inhibitor in phase 3 clinical trials for the treatment and prevention of HIV. CAB undergoes glucuronidation via UGT1A1 with <1% renal elimination of unchanged CAB. Renal impairment may affect PK of drugs that are primarily metabolized or secreted in...
Na minha lista:
| Udgivet i: | Open Forum Infect Dis |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Oxford University Press
2017
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5631309/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofx163.1085 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|